Figure 1.
This figure describes our patient cohort. 32,480 patients were included in prevalence analyses and 28,895 patients were included in outcome analysis. BRAF alteration was detected in 969 (2.98%) patients. In this cohort 271 patients had evaluable survival outcomes and had treatment information.

Consort diagram. aOwsley et al.14 Abbreviations: CCA, cholangiocarcinoma; GEA, gastroesophageal cancer; HCC, hepatocellular carcinoma, PDAC, pancreatic cancer.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close